Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Algernon Pharmaceuticals Inc
(OP:
AGNPF
)
0.0873
+0.0100 (+12.94%)
Streaming Delayed Price
Updated: 12:40 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Algernon Pharmaceuticals Inc
< Previous
1
2
Next >
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
April 17, 2024
Via
Benzinga
DMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial Design
April 03, 2024
Via
Benzinga
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
August 14, 2023
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published
Via
Benzinga
DMT As A Treatment For Stroke? This Company Is Closer To Launching Its Phase 2 Study
August 08, 2023
Algernon NeuroScience (AGN Neuro), a subsidiary of Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) (CSE:AGN) (FRANKFURT:AGW0), has completed a feasibility study and has finalized its clinical trial design...
Via
Benzinga
Algernon Posts Mixed Bag Results From Mid Stage Chronic Cough Study
July 18, 2022
Via
Benzinga
DMT's Clinical Path For Treating TBI And Stroke: Phase 1 Dosing Finished As Phase 2 Gears Up
June 05, 2023
Algernon Pharmaceuticals’ (OTCQB: AGNPF) wholly-owned Algernon NeuroScience (AGN Neuro) successfully completed dosing the third and final cohort of its Phase 1 clinical study assessing an intravenous...
Via
Benzinga
How To Finance A Psychedelics Business? Learn From These Four Companies
April 04, 2023
Clearmind Medicine Announces Pricing of $3.5 Million Public Offering
Via
Benzinga
Intravenous DMT Therapy Seeks Ideal Dosage For Stroke And TBI Treatment
April 04, 2023
Canadian biopharma company Algernon Pharmaceuticals Inc.
Via
Benzinga
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
March 07, 2023
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been...
Via
Benzinga
Algernon Pharmaceuticals AP-188 DMT Compound Shows Promise For The Treatment Of TBI
March 03, 2023
In this new podcast, TDR Founder Shadd Dales interviewed Algernon Pharmaceuticals (OTC: AGNPF) CEO, Christopher Moreau.
Via
Benzinga
Algernon Pharmaceuticals Goes 4:1 In Forward Share Split After Announcing New TBI Program
March 01, 2023
Canadian clinical-stage psychedelics developer Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) will start trading its Class A common shares following a 4-to-1 stock split towards increasing liquidity.
Via
Benzinga
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
February 27, 2023
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and...
Via
Benzinga
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
February 21, 2023
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and...
Via
Benzinga
Developing Psychedelic Treatments For Traumatic Brain Injury: Algernon Launches New Program
February 21, 2023
Biopharma company Algernon Pharmaceuticals (OTCQB: AGNPF) has launched a new clinical research program via a subsidiary.
Via
Benzinga
Algernon Touts Positive Study Findings, Confirms Next Trial Phase With Escalated Dose
February 16, 2023
Algernon Pharmaceuticals (OTCQB: AGNPF)’s subsidiary Algernon NeuroScience has completed the first cohort in its Phase 1 clinical study of
Via
Benzinga
A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Begins Dosing
January 18, 2023
Canadian clinical-stage psychedelics company Algernon Pharmaceuticals (OTCQB: AGNPF)’s newly created subsidiary Algernon NeuroScience (AGN Neuro) has dosed
Via
Benzinga
Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One
January 03, 2023
The psychedelics space is up and running. Together with the start of the new year, two companies have shared their latest financial decisions toward advancing their medical business programs.
Via
Benzinga
EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans
December 15, 2022
Part one of a three-part series. The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.
Via
Benzinga
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
November 21, 2022
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy
Via
Benzinga
Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon
November 16, 2022
Canadian clinical-stage psychedelics company Algernon Pharmaceuticals Inc.
Via
Benzinga
Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial, CEO Clips Video
November 08, 2022
Vancouver, British Columbia--(Newsfile Corp. - November 8, 2022) - Algernon Pharmaceuticals (CSE: AGN) (OTCQB: AGNPF) – The company is focused on...
Via
Newsfile
Tackling Depression With Psychedelics: New Phase 2 Clinical Study Begins At Yale University
October 24, 2022
Canadian-based psychedelics biopharma company Algernon Pharmaceuticals Inc.
Via
Benzinga
A Foundational Study On Stroke Is Ready. Here Is Why It's Important
September 12, 2022
Biopharma company Algernon Pharmaceuticals Inc's (OTC: AGNPF) recently announced plan for a Phase 1 clinical study on DMT for huma
Via
Benzinga
Canadian Psychedelics Company To Begin First Global DMT Clinical Trial For Stroke Treatment
September 08, 2022
Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has set up a clinical research program for the treatment of strokes, focused on its proprietary DMT analogue, AP-188. The company is also planning to begin...
Via
Benzinga
Algernon Pharmaceuticals Closes Private Placement Round, Announces New Shareholder Distribution
August 23, 2022
Biotech clinical-stage company Algernon Pharmaceuticals Inc.
Via
Benzinga
The Power Play by The Market Herald Releases New Interviews with Datametrex, Group Ten Metals, Algernon Pharmaceuticals and Alianza Minerals Discussing Their Latest News
November 01, 2021
VANCOUVER, BC / ACCESSWIRE / November 1, 2021 / The Power Play by The Market Herald has announced the release of new interviews with Datametrex, Group Ten Metals, Algernon Pharmaceuticals and Alianza...
From
The Market Herald
Via
AccessWire
The Power Play by The Market Herald Announces Interviews with Algernon Pharmaceuticals, NextechAR, UCore Rare Metals, Falcon Gold, and Durango Resources on Latest Company News
October 15, 2021
VANCOUVER, BC / ACCESSWIRE / October 15, 2021 / The Market Herald, the leading source of authoritative breaking stock market news for self-directed investors spoke with Algernon Pharmaceuticals, UCore...
From
The Market Herald
Via
AccessWire
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
October 18, 2021
The Week In Psychedelics
Via
Benzinga
Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics
September 13, 2021
Last Week In Psychedelics:
Via
Benzinga
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
October 13, 2021
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.